Reactive Oxygen Species : Network Pharmacology and Therapeutic Applications / edited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado.

Format:

Book

Contributor:

Schmidt, Harald H. H. W., editor.

Ghezzi, P. (Pietro), editor.

Cuadrado, Antonio, editor.

Series:

Handbook of Experimental Pharmacology, 1865-0325 ; 264

Language:

English

Subjects (All):

Pharmacology.

Cardiology.

Neurosciences.

Clinical biochemistry.

Neuroscience.

Medical Biochemistry.

Local Subjects:

Pharmacology.

Cardiology.

Neuroscience.

Medical Biochemistry.

Physical Description:

1 online resource (421 pages).

Edition:

1st ed. 2021.

Place of Publication:

Cham : Springer International Publishing : Imprint: Springer, 2021.

Summary:

Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term ‘oxidative stress’ is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference forROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.

Contents:

Part I: ROS Revisited: Changing the Focus from Oxidative Stress and Redox Biology to Redox Medicine

Demystifying oxidative stress

Oxidants in Physiological Processes

Network Medicine-Based Unbiased Disease Modules for Drug and Diagnostic Target Identification in ROSopathies

Part II Targeting antioxidant responses

Development of Telintra as an Inhibitor of Glutathione S-Transferase P

Perspectives on the Clinical Development of NRF2-Targeting Drugs

Part III: Inhibiting ROS formation and toxification

NOX Inhibitors: From Bench to Naxibs to Bedside

Nitric Oxide Synthase Inhibitors into the Clinic at Last

Xanthine Oxidoreductase Inhibitors

Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches

Inhibition of Myeloperoxidase

Part IV: Stimulating/substituting ROS

Effects of Mammalian Thioredoxin Reductase Inhibitors

Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation

Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers

Part V: Repairing ROS damage

Soluble Guanylate Cyclase Stimulators and Activators – Peter Sander

Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

ISBN:

3-030-68510-1

OCLC:

1241448315